The clinical trial report, “Parkinson's Disease - Global Clinical Trials Review, 2026" provides an overview of Parkinson's Disease Clinical trials scenario. This report provides top line data relating to the clinical trials on Parkinson's Disease. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). The analyst Clinical Trial Reports are generated using the analyst’s proprietary database - Pharma - Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.
The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.
Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.
Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Report Scope
- The report provides a snapshot of the global clinical trials landscape
- Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
- The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
- The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
- The Report provides enrollment trends for the past five years
- Report provides latest news for the past three months
Reasons to Buy
- Assists in formulating key business strategies with regards to investment
- Helps in identifying prominent locations for conducting clinical trials which saves time and cost
- Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities
- Supports understanding of trials count and enrollment trends by country in global therapeutics market
- Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
- Facilitates clinical trial assessment of the indication on a global, regional and country level
Table of Contents
- Report Guidance
- The analyst Clinical Trials Report Coverage
- Clinical Trials by Region
- Clinical Trials and Average Enrollment by Country
- Top Five Countries Contributing to Clinical Trials in Asia-Pacific
- Top Five Countries Contributing to Clinical Trials in Europe
- Top Countries Contributing to Clinical Trials in North America
- Top Five Countries Contributing to Clinical Trials in Middle East and Africa
- Top Five Countries Contributing to Clinical Trials in Central and South America
- Clinical Trials by G7 Countries: Proportion of Parkinson's Disease to Central Nervous System Clinical Trials
- Clinical Trials by Phase in G7 Countries
- Clinical Trials in G7 Countries by Trial Status
- Clinical Trials by E7 Countries: Proportion of Parkinson's Disease to Central Nervous System Clinical Trials
- Clinical Trials by Phase in E7 Countries
- Clinical Trials in E7 Countries by Trial Status
- Clinical Trials by Phase
- In Progress Trials by Phase
- Clinical Trials by Trial Status
- Clinical Trials by End Point Status
- Subjects Recruited Over a Period of Time
- Clinical Trials by Sponsor Type
- Prominent Sponsors
- Top Companies Participating in Parkinson's Disease Therapeutics Clinical Trials
- Prominent Drugs
- Latest Clinical Trials News on Parkinson's Disease
- Jan 27, 2026: Bial Achieves Key Milestone in Phase 2B ACTIVATE Study of BIA 28-6156 in GBA1-Associated Parkinson’s Disease
- Jan 23, 2026: Insilico Medicine Receives IND Approval From FDA for ISM8969, an AI-Empowered Potential Best-In-Class NLRP3 Inhibitor
- Jan 20, 2026: Olatec Therapeutics Presented Preclinical Evidence of Disease-Modifying Activity with Dapansutrile in its Parkinson's Studies
- Jan 15, 2026: Brenig Therapeutics Provides Update on BT-267, its LRRK2 Program
- Jan 15, 2026: Brenig Therapeutics Announces Initiation of First-in-Human Study of BT-409, a Brain-Selective NLRP3 Inhibitor
- Jan 09, 2026: NRG doses first participants in Phase I trial for ALS and Parkinson’s
- Jan 08, 2026: BioVie Completes Enrollment in Phase 2 SUNRISE-PD Trial in Early Parkinson’s Disease
- Jan 07, 2026: Herantis Pharma - Phase 1B Biomarker Data Show Clear Evidence of Biological Response to Her-096 in People With Parkinson’s Disease
- Jan 07, 2026: Bial Launches KYNMOBI (Apomorphine Hydrochloride) in the United Kingdom
- Jan 06, 2026: Gain Therapeutics Highlights Biomarker Evidence Supporting Disease-Modifying Potential of GT-02287
- Jan 05, 2026: Kenai Receives $8M Grant from California Institute for Regenerative Medicine (CIRM) to Advance RNDP-001 for Idiopathic Parkinson's Disease
- Dec 23, 2025: Parkinson’s stem cell therapy demonstrates promise in Phase II trial
- Dec 23, 2025: IRLAB Receives Approval for a Phase Ib Study with IRL757 in Parkinson's Disease
- Dec 22, 2025: Zambon Biotech Announces First Patient Dosed in Phase 3B ADIP Clinical Study of IPX203 in Parkinson’s Disease
- Dec 18, 2025: Gain Therapeutics Announces Positive Results in Key Exploratory Endpoint From Its Phase 1B Clinical Study of GT-02287 in People With PD
- Dec 18, 2025: Gain Therapeutics to Virtual KOL Event on GT-02287 for Parkinson’s Disease
- Dec 15, 2025: Kenai Announces First Patient Dosed in Phase 1 REPLACE Clinical Trial of Neuron Replacement Cell Therapy RNDP-001 for Idiopathic Parkinson's Disease
- Dec 11, 2025: AC Immune Positive Interim Phase 2 Data on ACI-7104.056 Support Potential Slowing of Progression of Parkinson’s Disease
- Dec 10, 2025: Serina Therapeutics Submits Complete Response to FDA Clinical Hold Letter for SER-252 Program
- Dec 09, 2025: AskBio’s AB-1005 Receive Pioneering Regenerative Medical Product Designation in Japan
- Dec 05, 2025: Amneal Announces Positive Interim Phase 4 ELEVATE-PD Results With CREXONT for Parkinson’s Disease
- Dec 05, 2025: Cerevance Showcases Positive Phase 2 Results Demonstrating Reduction in OFF Time with Solengepras as an Adjunctive Treatment in Parkinson’s Disease
- Nov 26, 2025: Herantis Pharma Announces Successful Completion of Six-Month GLP Toxicology Study of HER-096
- Nov 24, 2025: Cerevance to Highlight Potential of Solengepras in Parkinson’s Disease at the 2025 Parkinson Study Group Annual Meeting
- Nov 24, 2025: Annovis Announces Two Presentations at the CTAD 2025 Conference
- Nov 24, 2025: Approval Obtained for the Group’s New Drug LY03017 for Clinical Trials in the U.S.
- Nov 20, 2025: Gain Therapeutics Presents Preclinical GT-02287 Data at Neuroscience 2025
- Nov 17, 2025: Annovis Reports New Biomarker Data Linking Amyloid Co-Pathology to Accelerated Cognitive Decline in Parkinson's Patients
- Nov 17, 2025: Karolinska Portfolio Company Umecrine Cognition Publishes Data on the Benefits of Early Treatment With Golexanolone in Parkinson’s Disease
- Nov 15, 2025: BrainXell Showcases Pioneering iPSC Research and Promising In Vivo Data for BXT-110 for Parkinson's Disease at 2025 Society for Neuroscience Meeting
- Nov 13, 2025: Booster Therapeutics Awarded Grant From the Michael J. Fox Foundation for Parkinson’s Research (MJFF) to Advance New Class of Phase 1 Study
- Nov 13, 2025: Aldeyra Therapeutics Announces Expansion of RASP Platform To Include Central Nervous System Diseases and Provides Updates on Reproxalap
- Nov 11, 2025: CND Life Sciences’ Syn-One Biomarker Services Used for Novel Parkinson’s Disease Endpoint in Phase 2 Drug Trial
- Nov 07, 2025: IRLAB Receives Acceptance for Two Abstracts at AD/PD(TM) 2026: The 20th International Conference on Alzheimer's and Parkinson's Diseases
- Nov 05, 2025: Jupiter Neurosciences Receives FDA Clearance of IND Application To Initiate Phase 2A Clinical Trial of JOTROL in Parkinson’s Disease
- Nov 03, 2025: Serina Therapeutics Provides Regulatory Update on SER-252 Program
- Nov 03, 2025: BrainXell Unveils Promising Preclinical Data Demonstrating Efficacy of BXT-110, an Autologous iPSC-Derived Neuronal Therapy, in Parkinson's Disease
- Clinical Trial Profile Snapshots
- Appendix
- Abbreviations
- Definitions
- Research Methodology
- Secondary Research
- About the Analyst
- Contact the Publisher
- Source
- Parkinson's Disease Therapeutics, Global, Clinical Trials by Region, 2026*
- Parkinson's Disease Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2026*
- Parkinson's Disease Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2026*
- Parkinson's Disease Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2026*
- Parkinson's Disease Therapeutics Clinical Trials, Europe, Top Five Countries, 2026*
- Parkinson's Disease Therapeutics Clinical Trials, North America, Top Countries, 2026*
- Parkinson's Disease Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries, 2026*
- Parkinson's Disease Therapeutics Clinical Trials, Central and South America, Top Five Countries, 2026*
- Proportion of Parkinson's Disease to Central Nervous System Clinical Trials, G7 Countries (%), 2026*
- Parkinson's Disease Therapeutics, G7 Countries, Clinical Trials by Phase, 2026*
- Parkinson's Disease Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2026*
- Proportion of Parkinson's Disease to Central Nervous System Clinical Trials, E7 Countries (%), 2026*
- Parkinson's Disease Therapeutics, E7 Countries, Clinical Trials by Phase, 2026*
- Parkinson's Disease Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2026*
- Parkinson's Disease Therapeutics, Global, Clinical Trials by Phase, 2026*
- Parkinson's Disease Therapeutics, Global, Clinical Trials In Progress by Phase 2026*
- Parkinson's Disease Therapeutics, Global, Clinical Trials by Trial Status, 2026*
- Parkinson's Disease Therapeutics Clinical Trials, Global, by End Point Status, 2026*
- Parkinson's Disease Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2021-2025
- Parkinson's Disease Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2026*
- Parkinson's Disease Therapeutics Clinical Trials, Global, Key Sponsors, 2026*
- Parkinson's Disease Therapeutics Clinical Trials, Global, Top Companies by Phase, 2026*
- Parkinson's Disease Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2026*
- Parkinson's Disease Therapeutics, Global, Clinical Trials by Region (%), 2026*
- Parkinson's Disease Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2026*
- Parkinson's Disease Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2026*
- Parkinson's Disease Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2026*
- Parkinson's Disease Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2026*
- Parkinson's Disease Therapeutics Clinical Trials, North America, Top Countries (%), 2026*
- Parkinson's Disease Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries (%), 2026*
- Parkinson's Disease Therapeutics Clinical Trials, Central and South America, Top Five Countries (%), 2026*
- Proportion of Parkinson's Disease to Central Nervous System Clinical Trials, G7 Countries (%), 2026*
- Parkinson's Disease Therapeutics, G7 Countries, Clinical Trials by Phase, 2026*
- Parkinson's Disease Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2026*
- Proportion of Parkinson's Disease to Central Nervous System Clinical Trials, E7 Countries (%), 2026*
- Parkinson's Disease Therapeutics, E7 Countries, Clinical Trials by Phase, 2026*
- Parkinson's Disease Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2026*
- Parkinson's Disease Therapeutics, Global, Clinical Trials by Phase (%), 2026*
- Parkinson's Disease Therapeutics, Global, Clinical Trials In Progress by Phase, 2026*
- Parkinson's Disease Therapeutics, Global, Clinical Trials by Trial Status, 2026*
- Parkinson's Disease Therapeutics Clinical Trials, Global, by End Point Status, 2026*
- Parkinson's Disease Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2021-2025
- Parkinson's Disease Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2026*
- Parkinson's Disease Therapeutics Clinical Trials, Global, Key Sponsors, 2026*
- Parkinson's Disease Therapeutics Clinical Trials, Global, Top Companies by Phase, 2026*
- Parkinson's Disease Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2026*
- The analyst Methodology
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- AbbVie Inc
- UCB SA
- Teva Pharmaceutical Industries Ltd
- Bial Holding SA
- C. H. Boehringer Sohn AG & Co KG
- The Lundbeck Foundation
- Newron Pharmaceuticals SpA
- Novartis AG
- Kirin Holdings Co Ltd
- Pfizer Inc
